-+ 0.00%
-+ 0.00%
-+ 0.00%

60 Degrees Pharma Launches B-FREE Study, First-Ever Trial for Chronic Babesiosis Treatment

Benzinga·10/09/2025 11:18:33
Listen to the news

 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the name of its chronic babesiosis trial is the B-FREE Chronic Babesiosis Study.

The B-FREE study (NCT06656351), the first in the world to evaluate a potential new therapeutic for chronic babesiosis, will run for approximately 12 months. It is a Phase 2 open-label study that will evaluate the efficacy and safety of the ARAKODA® regimen of tafenoquine over 90 days for resolution of severe fatigue, and parasite eradication in patients with chronic babesiosis, a potentially disabling condition carried by the same tick that spreads Lyme disease.

No U.S. Food and Drug Administration-approved drug or professional society-recommended treatment for chronic babesiosis is currently available.